Bionor has acquired its 3rd HIV vaccine candidate, CRX.
Oslo, January 10, 2019 The acquisition is in the form of an exchange of patents and rights between Bionor and Immunor AS. During Bionor’s equity raise in December 2017, Bionor pledged to dispose of all its non-HIV activities. These activities have now been transferred to Immunor through a mutual assignment agreement where Immunor acquires all …